Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 20, 2025 04:00 ET | Source: Alvotech

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

REYKJAVIK, Iceland and LONDON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
November 12, 2025 16:40 ET | Source: Alvotech

Alvotech kynnir uppgjör fyrstu níu mánaða ársins 2025 og helstu áfanga í rekstri félagsins

Heildartekjur á fyrstu níu mánuðum ársins voru 420 milljónir dollara, sem er 24% aukning frá sama tímabili í fyrraTekjur af sölu vöru og þjónustu á fyrstu níu mánuðum ársins voru 237 milljónir...
November 12, 2025 16:40 ET | Source: Alvotech

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine...
November 12, 2025 16:40 ET | Source: Alvotech

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine...
November 06, 2025 09:00 ET | Source: Alvotech

Alvotech og Advanz Pharma fá markaðsleyfi í Bretlandi fyrir Gobivaz, hliðstæðu við Simponi (golimumab)

REYKJAVÍK OG LONDON (6. OKTÓBER 2025) - Breska lyfjastofnunin (MHRA) hefur veitt markaðsleyfi fyrir allar útgáfur Gobivaz, hliðstæðu Alvotech við líftæknilyfið Simponi (golimumab). Samstarfsaðili...
November 06, 2025 09:00 ET | Source: Alvotech

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

REYKJAVIK, ICELAND and LONDON, UK (November 06, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide...
November 02, 2025 17:12 ET | Source: Alvotech

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
October 22, 2025 05:00 ET | Source: Alvotech

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

REYKJAVIK, Iceland, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
October 06, 2025 04:40 ET | Source: Alvotech

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

LONDON and REYKJAVIK, Iceland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty,...
September 04, 2025 09:15 ET | Source: Alvotech

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

REYKJAVIK, Iceland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...